A phase I/II study of S-1+Irinotecan+panitumumab as first line treatment to advanced colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: S-1 80mg/m2 Oral administration day1-15 Irinotacan 150mg/m2 90min div day 1 Panitumumab 9mg/m2 90-30min div day 1 A single course to three weeks. Primary outcome(s): phase I: Estimated percentage of dose-limiting toxicity at first course. phase II: Response rate Study Design: Single arm Non-randomized
创建时间：
2011-03-15
